October 24th 2024
Nina Vadiei, PharmD, BCPP, a clinical associate professor at UT Austin and a clinical pharmacy specialist in psychiatry at San Antonio State Hospital, discusses her career as a psychiatric pharmacist.
Study on schizophrenia deaths makes surprising find
May 17th 2012A unique study designed to gauge the impacts of polypharmacy on schizophrenia mortality produced some surprising results: The use of antidepressants or 2 or more antipsychotics was not associated with increased deaths, but the use of benzodiazepine was.
Vitamin D threshold varies with season, study shows
May 17th 2012Researchers from the University of Washington have identified a threshold concentration of serum 25-hydroxyvitamin D [25-(OH)D] that is associated with increased risk for major medical events and they say that season-specific targets may be more appropriate than static targets when evaluating health risk.
Improved medication adherence: A growing movement in search of a leader
May 15th 2012There are many forces in play that can and should "converge to support better medication management and improved adherence," according to Tom Hubbard of the New England Healthcare Institute (NEHI), but coordination and leadership will be crucial.
Hospira recalls one lot of hydromorphone injection
May 14th 2012Hospira is voluntarily recalling one lot of hydromorphone injection, USP, 1 mg/mL (C-II), 1-mL fill in 2.5-mL Carpuject, NDC 0409-1283-31, after complaints that a single Carpuject contained more than the 1-mL labeled fill volume, according to a press release posted on the FDA website.
Retail pharmacists can help smokers kick the habit
May 8th 2012The percentage of Americans who are able to quit smoking has decreased over the past 2 decades, according to a new report, but retail pharmacists can play a key role in reversing that trend, one of the leaders of a team of tobacco researchers told Drug Topics.
Omega-3 shows no benefit for multiple sclerosis, study finds
May 3rd 2012The supplementation with omega-3 fatty acids has no benefit in treating multiple sclerosis, according to a clinical trial that appeared in the JAMA's Archives of Neurology. However, researchers acknowledged the randomized controlled trial was underpowered.